Applied Bio invests in sequencing company VisiGen

"We have been impressed by the significant progress VisiGen has made with relatively limited resources," says Philippe Nore, senior director of strategic planning with Applied Bio. "We are strong believers that this technology will ultimately deliver the best aternative. Cluster sequencing may be a bit ahead right now, but we are willing to wait the extra time for what we believe will be a better technology in the long term."